

**Review Form 1.7**

Journal Name:	Asian Journal of Research and Reports in Ophthalmology
Manuscript Number:	Ms_AJRROP_110593
Title of the Manuscript:	HYPHEMA POST INTRAVITREAL INJECTION OF BEVACIZUMAB
Type of the Article	Case study

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
--	---------------------------	---

## Review Form 1.7

<p><b>Compulsory</b> REVISION comments</p> <ol style="list-style-type: none"><li><b>1. Is the manuscript important for scientific community?</b> (Please write few sentences on this manuscript)</li><li><b>2. Is the title of the article suitable?</b> (If not please suggest an alternative title)</li><li><b>3. Is the abstract of the article comprehensive?</b></li><li><b>4. Are subsections and structure of the manuscript appropriate?</b></li><li><b>5. Do you think the manuscript is scientifically correct?</b></li><li><b>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</b></li></ol> <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p><b>Yes. The manuscript gives insight into a relatively rare complication of intravitreal injection</b></p> <p><b>Yes.</b></p> <p><b>No. Unstructured abstract with very little detail and no keywords.</b></p> <p><b>Yes. However, the clinical presentation section can be better structured (mentioned in general comments).</b></p> <p><b>No. It does not answer many questions (mentioned in general comments) and lacks relevant clinical photographs.</b></p> <p><b>No. Only 7 references, the latest being 10 years old. The first reference cannot be accessed.</b></p>	
<p><b>Minor</b> REVISION comments</p> <ol style="list-style-type: none"><li><b>1. Is language/English quality of the article suitable for scholarly communications?</b></li></ol>	<p><b>No. The article should be written in well structured and complete paragraphs.</b></p>	

## Review Form 1.7

Optional/General comments

### **ABSTRACT**

1. Please write a structured abstract as per journal guidelines.
2. Please provide some more details utilising the word limit.
3. What does the author mean by “normal clinical exam”?
4. Please mention if resolution of hyphema was with or without treatment and whether treatment was conservative, medical or surgical.
5. Please provide 4-5 keywords.

### **GENERAL REMARKS**

6. Please write reference numbers in brackets [] at the end of sentences as per journal guidelines.
7. Please write the manuscript in structured and complete paragraphs. Avoid use of broken/incomplete sentences.

### **INTRODUCTION**

8. Please mention recent reference for “treatment in its exudative form relies on intravitreal anti-VEGF injections of Bevacizumab or Ranibizumab”.
9. Please mention reference for “All these complications occur at a rate of less than 0.1%”.
10. Please mention if informed consent has been obtained from the patient and provide the consent form as per journal guidelines.

### **CASE PRESENTATION**

11. It is suggested to write the case presentation in a structured form including history, clinical examination, investigations, diagnosis, management and follow up.
12. In which region was this case seen?
13. Age of the patient mentioned in abstract (54) is different from that mentioned in case presentation (52).
14. Patient history should include onset and progression, any specific risk factors or absence thereof.
15. Please mention standard by which visual acuity has been assessed.
16. How was the diagnosis of exudative AMD arrived at based on only clinical finding of “poor macular reflex”, without supportive investigations such as OCT macula or FFA?
17. Please provide colour fundus photographs of the patient.
18. Please provide relevant photographs of investigations (OCT, FFA) of the patient.
19. What was the rationale for using off-label drug Bevacizumab for the treatment of the patient in the presence of more recent guidelines advocating Aflibercept and Ranibizumab as first line treatments for exudative AMD [ref VIEW1, VIEW2, MARINA, ANCHOR, PIER trials].
20. Please include relevant serial anterior segment photographs to show complete hyphema and states of resolution.

### **DISCUSSION**

21. Please mention correct classification of AMD with reference.
22. Incorrect spelling of hyphema (hyphemia) has been noted at two places. Kindly rectify.
23. Were permissions obtained for images produced from other sources/literature? If yes, please mention in caption and provide evidence of the same. If not, please remove them and include more clinical photographs of the patient reported (preferably suggested given the limit of 5 images).
24. What was the cause of hyphema in this patient? Was abnormal anatomy ascertained using ASOCT/UBM?
25. What precautions could be taken to avoid such a complication in the future?

### **CONCLUSION**

26. What does the author mean by “good prognosis under proper rehydration”?
27. Please include conflicts of interest and financial disclosures after conclusion.

### **REFERENCES**

28. Please include more references and some more recent references. Please ensure the references are relevant to the manuscript.
29. Please ensure uniform reference styling as per journal guidelines. Also mention the doi, PMID, PMCID of the cited articles for easy access.

## Review Form 1.7

### **PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

### **Reviewer Details:**

Name:	<b>Anuradha</b>
Department, University & Country	<b>Military Hospital, India</b>